Novel Galactose Single Point Method as a Measure of Residual Liver Function: Example of Cefoperazone Kinetics in Patients with Liver Cirrhosis

Oliver Yoa‐Pu Hu, Hung‐Shang ‐S Tang, Ching‐Ling ‐L Chang

研究成果: 雜誌貢獻文章

12 引文 (Scopus)

摘要

A novel, simple, clinically useful quantitative liver function test, called the galactose single point (GSP) method, was developed to assess residual liver function by measuring galactose blood concentration 1 hour after galactose was administered (0.5 g/kg). This method was applied to the study of cefoperazone kinetics in patients with hepatic cirrhosis. To study the influence of hepatic cirrhosis on the residual liver function and the correlation between the residual liver function and the pharmacokinetics of cefoperazone, a dose of 1 g of cefoperazone was administered to 11 healthy volunteers and 12 patients with liver cirrhosis. The GSP method, the galactose elimination capacity (GEC) test, and the modified galactose elimination capacity (MGEC) test were done for each volunteer and patient to measure residual liver function. The galactose concentrations were determined enzymatically. Cefoperazone was administered intravenously, and blood and urine samples were collected at appropriate intervals after drug administration. All blood and urine samples were stored at −30°C until high‐performance liquid chromatography analysis. Cefoperazone plasma concentrations were much higher in cirrhosis patients than in normal subjects at all times. The elimination half‐life, hepatic clearance, mean residence time, and renal clearance of cirrhosis patients differed significantly from those of healthy volunteers. The plasma protein binding was unaltered in both groups. Urinary excretion of cefoperazone was significantly increased in cirrhosis patients (23.95 ± 5.06% for normal men and 51.09 ± 11.50% in cirrhosis patients). Hepatic clearance, fraction excreted in urine, and total clearance significantly correlated with GSP, GEC, and MGEC (P < .001). These results suggest that (1) cefoperazone kinetics was significantly altered in patients with cirrhosis; and (2) the GSP method can predict the cefoperazone clearances in patients with liver dysfunction. 1995 American College of Clinical Pharmacology
原文英語
頁(從 - 到)250-258
頁數9
期刊The Journal of Clinical Pharmacology
35
發行號3
DOIs
出版狀態已發佈 - 一月 1 1995
對外發佈Yes

指紋

Cefoperazone
Galactose
Liver Cirrhosis
Liver
Fibrosis
Urine
Healthy Volunteers
Clinical Pharmacology
Liver Function Tests
Protein Binding
Liquid Chromatography
Half-Life
Liver Diseases
Blood Proteins
Volunteers
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

引用此文

Novel Galactose Single Point Method as a Measure of Residual Liver Function : Example of Cefoperazone Kinetics in Patients with Liver Cirrhosis. / Hu, Oliver Yoa‐Pu; Tang, Hung‐Shang ‐S; Chang, Ching‐Ling ‐L.

於: The Journal of Clinical Pharmacology, 卷 35, 編號 3, 01.01.1995, p. 250-258.

研究成果: 雜誌貢獻文章

Hu, Oliver Yoa‐Pu ; Tang, Hung‐Shang ‐S ; Chang, Ching‐Ling ‐L. / Novel Galactose Single Point Method as a Measure of Residual Liver Function : Example of Cefoperazone Kinetics in Patients with Liver Cirrhosis. 於: The Journal of Clinical Pharmacology. 1995 ; 卷 35, 編號 3. 頁 250-258.
@article{e600b4152c6b42bda66feb0e2f78761f,
title = "Novel Galactose Single Point Method as a Measure of Residual Liver Function: Example of Cefoperazone Kinetics in Patients with Liver Cirrhosis",
abstract = "A novel, simple, clinically useful quantitative liver function test, called the galactose single point (GSP) method, was developed to assess residual liver function by measuring galactose blood concentration 1 hour after galactose was administered (0.5 g/kg). This method was applied to the study of cefoperazone kinetics in patients with hepatic cirrhosis. To study the influence of hepatic cirrhosis on the residual liver function and the correlation between the residual liver function and the pharmacokinetics of cefoperazone, a dose of 1 g of cefoperazone was administered to 11 healthy volunteers and 12 patients with liver cirrhosis. The GSP method, the galactose elimination capacity (GEC) test, and the modified galactose elimination capacity (MGEC) test were done for each volunteer and patient to measure residual liver function. The galactose concentrations were determined enzymatically. Cefoperazone was administered intravenously, and blood and urine samples were collected at appropriate intervals after drug administration. All blood and urine samples were stored at −30°C until high‐performance liquid chromatography analysis. Cefoperazone plasma concentrations were much higher in cirrhosis patients than in normal subjects at all times. The elimination half‐life, hepatic clearance, mean residence time, and renal clearance of cirrhosis patients differed significantly from those of healthy volunteers. The plasma protein binding was unaltered in both groups. Urinary excretion of cefoperazone was significantly increased in cirrhosis patients (23.95 ± 5.06{\%} for normal men and 51.09 ± 11.50{\%} in cirrhosis patients). Hepatic clearance, fraction excreted in urine, and total clearance significantly correlated with GSP, GEC, and MGEC (P < .001). These results suggest that (1) cefoperazone kinetics was significantly altered in patients with cirrhosis; and (2) the GSP method can predict the cefoperazone clearances in patients with liver dysfunction. 1995 American College of Clinical Pharmacology",
author = "Hu, {Oliver Yoa‐Pu} and Tang, {Hung‐Shang ‐S} and Chang, {Ching‐Ling ‐L}",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/j.1552-4604.1995.tb04055.x",
language = "English",
volume = "35",
pages = "250--258",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Novel Galactose Single Point Method as a Measure of Residual Liver Function

T2 - Example of Cefoperazone Kinetics in Patients with Liver Cirrhosis

AU - Hu, Oliver Yoa‐Pu

AU - Tang, Hung‐Shang ‐S

AU - Chang, Ching‐Ling ‐L

PY - 1995/1/1

Y1 - 1995/1/1

N2 - A novel, simple, clinically useful quantitative liver function test, called the galactose single point (GSP) method, was developed to assess residual liver function by measuring galactose blood concentration 1 hour after galactose was administered (0.5 g/kg). This method was applied to the study of cefoperazone kinetics in patients with hepatic cirrhosis. To study the influence of hepatic cirrhosis on the residual liver function and the correlation between the residual liver function and the pharmacokinetics of cefoperazone, a dose of 1 g of cefoperazone was administered to 11 healthy volunteers and 12 patients with liver cirrhosis. The GSP method, the galactose elimination capacity (GEC) test, and the modified galactose elimination capacity (MGEC) test were done for each volunteer and patient to measure residual liver function. The galactose concentrations were determined enzymatically. Cefoperazone was administered intravenously, and blood and urine samples were collected at appropriate intervals after drug administration. All blood and urine samples were stored at −30°C until high‐performance liquid chromatography analysis. Cefoperazone plasma concentrations were much higher in cirrhosis patients than in normal subjects at all times. The elimination half‐life, hepatic clearance, mean residence time, and renal clearance of cirrhosis patients differed significantly from those of healthy volunteers. The plasma protein binding was unaltered in both groups. Urinary excretion of cefoperazone was significantly increased in cirrhosis patients (23.95 ± 5.06% for normal men and 51.09 ± 11.50% in cirrhosis patients). Hepatic clearance, fraction excreted in urine, and total clearance significantly correlated with GSP, GEC, and MGEC (P < .001). These results suggest that (1) cefoperazone kinetics was significantly altered in patients with cirrhosis; and (2) the GSP method can predict the cefoperazone clearances in patients with liver dysfunction. 1995 American College of Clinical Pharmacology

AB - A novel, simple, clinically useful quantitative liver function test, called the galactose single point (GSP) method, was developed to assess residual liver function by measuring galactose blood concentration 1 hour after galactose was administered (0.5 g/kg). This method was applied to the study of cefoperazone kinetics in patients with hepatic cirrhosis. To study the influence of hepatic cirrhosis on the residual liver function and the correlation between the residual liver function and the pharmacokinetics of cefoperazone, a dose of 1 g of cefoperazone was administered to 11 healthy volunteers and 12 patients with liver cirrhosis. The GSP method, the galactose elimination capacity (GEC) test, and the modified galactose elimination capacity (MGEC) test were done for each volunteer and patient to measure residual liver function. The galactose concentrations were determined enzymatically. Cefoperazone was administered intravenously, and blood and urine samples were collected at appropriate intervals after drug administration. All blood and urine samples were stored at −30°C until high‐performance liquid chromatography analysis. Cefoperazone plasma concentrations were much higher in cirrhosis patients than in normal subjects at all times. The elimination half‐life, hepatic clearance, mean residence time, and renal clearance of cirrhosis patients differed significantly from those of healthy volunteers. The plasma protein binding was unaltered in both groups. Urinary excretion of cefoperazone was significantly increased in cirrhosis patients (23.95 ± 5.06% for normal men and 51.09 ± 11.50% in cirrhosis patients). Hepatic clearance, fraction excreted in urine, and total clearance significantly correlated with GSP, GEC, and MGEC (P < .001). These results suggest that (1) cefoperazone kinetics was significantly altered in patients with cirrhosis; and (2) the GSP method can predict the cefoperazone clearances in patients with liver dysfunction. 1995 American College of Clinical Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0028900033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028900033&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1995.tb04055.x

DO - 10.1002/j.1552-4604.1995.tb04055.x

M3 - Article

C2 - 7608313

AN - SCOPUS:0028900033

VL - 35

SP - 250

EP - 258

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 3

ER -